Val­isure pres­sures FDA to re­call ac­ne treat­ments af­ter find­ing car­cino­gen

The drug test­ing com­pa­ny Val­isure is back with an­oth­er cit­i­zen pe­ti­tion re­lat­ed to safe­ty con­cerns, this time re­quest­ing the FDA re­call ac­ne treat­ments that con­tain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER